U.S. Markets closed

Incyte signs $77.5M collaboration and licensing deal with Chinese biopharmaceutical company

John George
Incyte signs $77.5M collaboration and licensing deal with Chinese biopharmaceutical company

The deal, which involves an Incyte monoclonal antibody being developed as a cancer treatment, includes a $17.5 million upfront payment.